<i>HER2</i> mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium

Abstract

HER2 mutations were detected in 3% of patients with lung adenocarcinoma in the LCMC. HER2-directed therapies should be investigated in this subgroup of patients. Cancer 2017;123:4099-4105. © 2017 American Cancer Society.